Mesenchymal hamartoma of the liver (MHL) is a rare benign tumor that often presents in early childhood, and it rarely occurs in adulthood. Aberrant development of the portal tract is a known cause of MHL. Although limited information is available on the natural course of MHL, malignant transformation has been reported in a few cases. Here, we report a case of a 26-year-old female with intrahepatic cholangiocarcinoma secondary to unresected MHL. The patient underwent resection of the hepatic mass, which was diagnosed as MHL at 2 years of age, due to an increase in mass size and a suspicion of malignant transformation during work-up. Histopathology confirmed intrahepatic adenosquamous carcinoma in the background of MHL, with a T2N0M0 pathological stage (stage II). The surgical margin was free from tumor cells. The patient fully recovered postoperatively and started receiving adjuvant chemotherapy. Previous case reports have only reported about the development of undifferentiated embryonal sarcoma or angiosarcoma as malignant transformation of MHL. Cases of other malignancies have not been published; however, it is difficult to rule out the occurrence of various malignancies related to the portal tract when considering the pathogenesis of the disease. To the best of our knowledge, this is the first case report of adenocarcinoma of bile duct origin secondary to MHL. This case report suggests that aggressive surgical management should be considered after the initial diagnosis of MHL.

**Key Words:** Hamartoma; Cholangiocarcinoma; Liver; Hepatectomy

**INTRODUCTION**

Mesenchymal hamartoma of the liver (MHL) is the second most common benign pediatric tumor, although its incidence is as low as 8% of all pediatric malignancies [1]. Moreover, 80% of patients are diagnosed before the age of 2 years, while the remaining 20% are diagnosed before the age of 5 years [2,3]. The occurrence of MHL in the adult population is very rare. A literature review by Klaassen et al. [4] presented only 31 published adult cases until 2010 [5]. MHL usually manifests as a cystic mass in the liver that occupies the intraperitoneal cavity and presents with vague symptoms. It is presumed that abnormal development of a complex mixture of immature mesenchymal tissues in the portal tract contributes to its pathogenesis. MHL is considered a benign tumor, and few studies have reported spontaneous resolution of the tumor [6,7]. The correct management of MHL remains controversial, but complete excision is recommended [8]. Complete resection usually achieves good outcomes without tumor recurrence, [8] which was also demonstrated in a retrospective study of nine patients followed up for 6.00 ± 2.78 years (range: 1–9 years) [9]. However, the prognosis of untreated tumors is not well understood. Several studies have reported about the development of undifferentiated embryonal sarcoma (UES) or angiosarcoma secondary to incompletely resected MHL [6,10]. Since the pri-
mary pathogenesis is dysgenesis of the portal tract, including the bile duct, and progression from bile duct hamartoma to intrahepatic cholangiocarcinoma (iCCA) has been reported in several studies. iCCA should be included in the differential diagnosis of malignant transformation of MHL \[11,12\]. These facts underline the importance of complete surgical resection and histopathological diagnosis. Here, we have presented a novel case of iCCA that developed 24 years after the initial diagnosis of MHL.

**CASE**

A 26-year-old female was admitted for MHL. At the age of 16 months, a mass measuring 9 cm × 8 cm with multiple septations in the right lobe of the liver was noted during the assessment of abdominal distension using ultrasonography (US) and magnetic resonance imaging (MRI) (Fig. 1A, 1B). Based on these findings, the patient was diagnosed with MHL. Liver enzyme levels were elevated, but not above three-fold of the upper limit. The serum α-fetoprotein (AFP) level was elevated to 39 mg/mL, while the carcinoembryonic antigen (CEA) level was elevated to 3 mg/mL. The MRI before the operation showed a complex solid, cystic mass with thick wall and calcification in the liver segment 6 is observed along with an increase in size (12.9 cm × 8.3 cm). In the portal phase, a peripheral enhancing lesion measuring 6 cm is seen in the posterior portion. This indicates the possibility of abscess formation or malignant transformation to undifferentiated embryonal sarcoma. (Fig. 1C) Computed tomography before the operation. A complex solid, cystic mass with thick wall and calcification in the liver segment 6 is observed along with an increase in size (12.9 cm × 8.3 cm). In the portal phase, a peripheral enhancing lesion measuring 6 cm is seen in the posterior portion. This indicates the possibility of abscess formation or malignant transformation to undifferentiated embryonal sarcoma. (Fig. 1D) MRI before the operation. In the T2 enhanced image, the lesion is observed with a solid component and peripheral rim-like enhancement along the posteroinferior portion of the mass. (E) F-18-fluorodeoxyglucose positron emission tomography (PET). The rim-like enhancement on MRI shows intense hypermetabolism on PET.
Progression of a persisting mesenchymal hamartoma to intrahepatic cholangiocarcinoma

3.3 ng/mL. However, the scheduled hepatic mass resection was cancelled due to an upper respiratory infection. Since this mass did not cause any symptoms, the patient underwent regular sonographic follow-up every 2 years until the age of 10 years. Subsequently, the patient was lost to follow-up. At the age of 26 years, the patient returned to our clinic with abdominal pain lasting for 6 weeks. Computed tomography (CT) revealed an increase in mass size to 12.9 cm × 8.3 cm and a newly developed peripheral enhancing lesion in its posterior portion measuring 6 cm (Fig. 1C). Follow-up MRI and 18F-fluorodeoxyglucose positron emission tomography (PET) could not exclude malignant transformation (Fig. 1D, 1E). In addition, enlarged lymph nodes (LN) in the hepatoduodenal ligament and portocaval space were also identified. Her liver function appeared to be normal. Mild elevation of the γ-glutamyl transpeptidase level to 40 IU/L (normal range: 8–35 IU/L) was observed. Preoperatively, the serum levels of tumor markers were as follows: AFP: 1.13 ng/mL (normal range: 0.89–8.78 ng/mL), CEA: 1.3 ng/mL (normal range: 0–5 ng/mL), and carbohydrate antigen 19-9 (CA 19-9): 1,075 U/mL (normal range: 0–37 U/mL). Mass excision with segment 5 and 6 hepatic segmentectomy (non-anatomical) and en bloc hilar LN dissection was performed. The mass was approached via an upper midline incision, and a mass measuring 16 cm was excised with a part of segments 5 and 6 of the liver parenchyma. Intraoperative frozen biopsy of the hilar LN showed no evidence of a tumor. Histopathological examination of the mass measuring 12.0 cm × 11.0 cm × 8.0 cm confirmed the diagnosis of iCCA in the background of MHL, with a T2N0M0 pathological stage (stage II). Although lymphatic and venous invasions were noted, the resection margin was free from tumor cells. Immunohistochemical analysis revealed cytokeratin (CK) 19 and p40 positivity and loss of p53 expression; thus, the final diagnosis was iCCA with squamous differentiation (Fig. 2). The patient recovered well postoperatively; however, a biloma was observed at the resection site, which required percutaneous drainage for 29 days. Furthermore, adjuvant chemotherapy (5-fluorouracil, 810 mg, six cycles) was initiated on postoperative day 60. After surgery and adjuvant chemotherapy, the serum levels of CEA and CA 19-9 decreased to 1.6 U/mL and 7 ng/mL, respectively (Fig. 3).

This study was approved by the Institutional Review Board of Seoul National University Hospital (2202-107-1302). Informed consent was obtained from the patient for data collection and publication of the study.

DISCUSSION

MHL is considered a benign tumor that mainly presents in the right lobe of the liver. It typically occurs in children aged

Fig. 2. Diagnosis of intrahepatic cholangiocarcinoma (CCA) in the background of mesenchymal hamartoma of the liver (MHL). On gross pathology, a mass (size: 12.0 cm × 11.0 cm × 8.0 cm) with a necrotic portion (10%) and calcification is observed. Histopathology reveals CCA in the background of mesenchymal hamartoma and indicates the presence of adenosquamous carcinoma with intrahepatic vascular invasion. Lymphatic and venous invasions are confirmed microscopically, although no perineural invasion is observed. Immunohistochemistry shows expression of cytokeratin (CK) 19 and p40 and loss of p53. This finding suggests a cancer with squamous differentiation. (A) Left ×2: Gross photos. Middle: H&E stain ×40. Right: H&E stain ×40. (B) CK19 stain (×40). (C) p40 stain (×40). (D) p53 stain (×40).
less than 2 years [13]. Although rare, MHL has been reported in older children and adults [4,5]. However, the reported adult cases provided insufficient information regarding whether the mass developed at the time of diagnosis or during childhood.

The clinical manifestations of MHL are diverse, ranging from painless abdominal distension to compromised liver function and symptoms (e.g., abdominal pain) due to an enlarged mass. In our case, an enlarged mass was incidentally found during work-up at 16 months of age. The patient had been asymptomatic for 24 years, developing abdominal pain only shortly before surgery.

Surgical resection is the treatment of choice in most review articles. Nevertheless, when a clinician or a patient decides not to operate MHL, the authors recommend a check-up with images and tumor markers (CA19-9 and CEA) at an interval of 6–12 months. However, there is no concrete evidence for the authors’ opinion.

US and CT are the diagnostic modalities of choice because they allow proper inspection of gross tumor features. On diagnostic imaging, MHL presents as a solitary mass, predominantly cystic, but it can present as a cystic, multicystic, or complex solid mass [14]. Cystic masses are visualized as multicystic and septated masses within the liver or on a pedicle. Low and high signal intensities are characteristic findings on T1- and T2-weighted MRI. Calcification, occasionally multifocal, may also be present. In contrast studies, the characteristic findings include enhancement of the solid component, abnormal blood vessels, and multiple focal avascular lesions in the cystic portion. The multiseptated mass in our patient persisted since the initial diagnosis, suggesting a cystic form of MHL, similar to the findings of follow-up US at the age of 5 years. However, CT performed at the age of 26 years revealed a rim enhancement inside the mass, arousing suspicion of abscess formation and malignant transformation, which was confirmed by subsequent MRI and PET. Since the patient was an adult with persisting MHL from 2 years of age, it was difficult to rule out malignant transformation; therefore, surgical treatment was considered as the first treatment option. Several studies have reported that UES can arise from incompletely resected MHL [8,10]. Recent studies have shown that MHL is associated with changes on chromosome 19, and it shares this genetic profile with UES secondary to MHL (rearrangement in the 19q13.4 region) [15]. However, none of the studies have reported an association between MHL and other cancers thus far.

The pedunculated mass was excised with a part of the liver parenchyma since complete excision was considered the best treatment option. Aspiration cytology performed during preoperative diagnosis mainly identified benign spindle cells mixed with myxoid stroma, normal ductal cells, and hepatocytes. Mesenchymal structures containing abnormal bile duct profiles and bile duct equivalents surrounding immature, partly myxoid mesenchyme with spindle cells and stellate cells are often seen in MHL [13]. Since microscopic examination of our patient’s material showed similar features, we concluded that the mass was MHL. Although these examinations were not performed due to the possibility of malignant transformation, we found evidence suggesting iCCA. Positive staining for vimentin and smooth muscle actin suggests MHL, whereas positive staining for CK-7 and CK-19 indicates the presence of bile duct-like structures. The expression of CK-19 in our patient indicated abnormal proliferation of bile ducts. iCCA is an adenocarcinoma arising from the intrahepatic bile ducts [16]. Loss of p53 expression implied malignant transformation. In addition, p53 is a diagnostic marker for iCCA [17]. Therefore, we concluded that iCCA developed in the background of MHL. Postoperative treatment was performed according to the guidelines for iCCA stating that complete resection is sufficient for MHL.

Abnormal development of the portal tract, including the bile duct, is the primary cause of MHL. Moreover, progression

![Fig. 3. Changes in the serum levels of tumor markers after treatment. Shortly after surgery, the levels of tumor markers were normalized. CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; OP, operation.](https://doi.org/10.14701/ahbps.22-022)
Progression of a persisting mesenchymal hamartoma to intrahepatic cholangiocarcinoma

from bile duct hamartoma to iCCA has been reported in previous studies [11,12]. Although the mechanism and histopathological association between MHL and bile duct hamartoma have not been uncovered since both hamartomas include bile duct structures, iCCA should be considered in the differential diagnosis when malignant transformation of MHL is suspected. Thus, en bloc surgical resection with negative surgical margins and histopathological diagnosis are more important.

MHL is a rare disease, with limited information available on its pathogenesis or long-term course. Here, we have reported a novel case of iCCA secondary to untreated MHL in a 26-year-old patient. Our findings differ from those of previously published reports on malignant transformation of MHL, such as progression to UES or angiosarcoma. The finding suggests that more aggressive surgical treatment is required for MHL. Early resection of MHL is recommended because of malignant transformation even in a child under 2 years of age. We anticipate that our finding will impact the treatment guidelines for MHL in the future.

FUNDING

None.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ORCID

Sujin Gang, https://orcid.org/0000-0003-1765-9437
YoungRok Choi, https://orcid.org/0000-0001-9776-6325
Sola Lee, https://orcid.org/0000-0001-6791-5668
Su young Hong, https://orcid.org/0000-0002-9934-0456
Sanggyun Suh, https://orcid.org/0000-0001-7985-2975
Eui Soo Han, https://orcid.org/0000-0001-9582-1255
Suk Kyun Hong, https://orcid.org/0000-0002-0020-6215
Nam-Joon Yi, https://orcid.org/0000-0002-5467-425X
Kwang-Woong Lee, https://orcid.org/0000-0001-6412-1926
Kyung-Suk Suh, https://orcid.org/0000-0002-9535-7349

AUTHOR CONTRIBUTIONS

Conceptualization: SG, YRC. Data curation: SG, YRC. Methodology: SG, YRC. Visualization: SG. Writing - original draft: SG, YRC. Writing - review & editing: SG, YRC. Manuscript revision & critical review: All authors.

REFERENCES

1. Chandramouleeswari K, Anita S, Shivali B. Mesenchymal hamartoma of the liver: a case report. J Clin Diagn Res 2012;6:1552-1554.
2. Yen JB, Kong MS, Lin JN. Hepatic mesenchymal hamartoma. J Paediatr Child Health 2003;39:632-634.
3. Wada M, Ohashi E, Jin H, Nishikawa M, Shintani S, Yamashita M, et al. Mesenchymal hamartoma of the liver: report of an adult case and review of the literature. Intern Med 1992;31:1370-1375.
4. Klaassen Z, Paragi PR, Chamberlain RS. Adult mesenchymal hamartoma of the liver: case report and literature review. Case Rep Gastroenterol 2010;4:84-92.
5. Cho HS, Lee OJ, Ha J, Lee EJ, Yoon JH, Min HJ, et al. Two cases of mesenchymal hamartoma of the liver in adult. Korean J Med 2003;65:355-360.
6. Stringer MD, Alizai NK. Mesenchymal hamartoma of the liver: a systematic review. J Pediatr Surg 2005;40:1681-1690.
7. Barnhart DC, Hirschcl RB, Garver KA, Geiger JD, Harmon CM, Coran AG. Conservative management of mesenchymal hamartoma of the liver. J Pediatr Surg 1997;32:1495-1498.
8. Meyers RL. Tumors of the liver in children. Surg Oncol 2007;16:195-203.
9. Pandey A, Gangopadhyay AN, Sharma SP, Kumar V, Gupta DK, Gopal SC, et al. Long-term follow up of mesenchymal hamartoma of liver: single center study. Saudi J Gastroenterol 2011;17:20-22.
10. Ramanujam TM, Ramesh JC, Goh DW, Wong KT, Ariffin WA, Kumar G, et al. Malignant transformation of mesenchymal hamartoma of the liver: case report and review of the literature. J Pediatr Surg 1999;34:1684-1686.
11. Shirazi N, Chauhan NV, Chandra S, Kumar SS. Von Meyenburg complex clinically presenting as metastatic liver nodule: a rare finding in an elderly male. J Lab Physicians 2019;11:385-387.
12. Yang XY, Zhang HB, Wu B, Li AJ, Fu XH. Surgery is the preferred treatment for bile duct hamartomas. Mol Clin Oncol 2017;7:649-653.
13. Zimmermann A. Tumors and tumor-like lesions of the hepatobiliary tract. Cham: Springer, 2017:1837-1855.
14. Kim SH, Kim WS, Cheon JE, Yoon HK, Kang GH, Kim JO, et al. Radiological spectrum of hepatic mesenchymal hamartoma in children. Korean J Radiol 2007;8:498-505.
15. O’Sullivan MJ, Swanson PE, Knoll J, Taboada EM, Dehner LP. Undifferentiated embryonal sarcoma with unusual features arising within mesenchymal hamartoma of the liver: report of a case and review of the literature. Pediatr Dev Pathol 2001;4:482-489.
16. Yamashita S, Morine Y, Imura S, Ikemoto T, Saito Y, Takesu C, et al. A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2. World J Surg Oncol 2021;19:142.
17. O’Dell MR, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grosse V, et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res 2012;72:1557-1567.